Applied Genetic Technologies Corp AGTC
We take great care to ensure that the data presented and summarized in this overview for APPLIED GENETIC TECHNOLOGIES CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in AGTC
Top Purchases
Top Sells
About AGTC
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was incorporated in 1999 and is headquartered in Alachua, Florida.
Insider Transactions at AGTC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 30
2022
|
Susan B. Washer President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
143,021
-100.0%
|
-
|
|
Nov 30
2022
|
Stephen W Potter Chief Business Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,750
-100.0%
|
-
|
|
Nov 30
2022
|
Stephen W Potter Chief Business Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
47,133
-84.34%
|
-
|
|
Nov 30
2022
|
Gerald Anthony Reynolds Chief Accounting Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
42,500
-100.0%
|
-
|
|
Nov 30
2022
|
Gerald Anthony Reynolds Chief Accounting Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
8,506
-16.68%
|
-
|
|
Nov 30
2022
|
Scott Koenig Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
34,246
-100.0%
|
-
|
|
Nov 30
2022
|
Edward Hurwitz Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
1,800
-100.0%
|
-
|
|
Nov 30
2022
|
Edward Hurwitz Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
25,672
-100.0%
|
-
|
|
Nov 30
2022
|
William Aliski Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
8,500
-100.0%
|
-
|
|
Nov 30
2022
|
James Rosen Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
1,000
-100.0%
|
-
|
|
Aug 21
2022
|
Gerald Anthony Reynolds Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+37.03%
|
-
|
|
Jul 01
2022
|
Stephen W Potter Chief Business Officer |
SELL
Open market or private sale
|
Direct |
8,070
-12.62%
|
$0
$0.77 P/Share
|
|
May 27
2022
|
Gerald Anthony Reynolds Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,994
-15.98%
|
$0
$0.85 P/Share
|
|
Feb 18
2022
|
Susan B. Washer President and CEO |
SELL
Open market or private sale
|
Direct |
9,950
-6.5%
|
$19,900
$2.18 P/Share
|
|
Feb 18
2022
|
Susan B. Washer President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
120,686
+44.1%
|
$0
$0.35 P/Share
|
|
Nov 01
2021
|
Susan B. Washer President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,877
+10.72%
|
$11,631
$3.5 P/Share
|
|
Aug 15
2021
|
Stephen W Potter Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,724
-8.22%
|
$17,172
$3.58 P/Share
|
|
Jun 17
2021
|
Stephen W Potter Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+33.44%
|
-
|
|
Dec 26
2019
|
Patrick Johan Hendrik Krol > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
81,162
-4.36%
|
$405,810
$5.24 P/Share
|
|
Nov 19
2019
|
Patrick Johan Hendrik Krol > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,544
+0.14%
|
$5,088
$2.79 P/Share
|